PleoPharma, Inc. is a clinical stage development company in the neuropsychology and addiction space focused on finding solutions for people suffering from cannabis addiction and other cannabis related health problems. PleoPharma’s mission is to provide therapies for those individuals seeking treatment for addictions where no FDA approved product or medical treatment exists.
The lead asset, PP-01, is being evaluated for the mitigation of Cannabis Withdrawal Syndrome (CWS) in patients with Cannabis Use Disorder (CUD). There are currently no FDA approved medications for the treatment of CWS or CUD. In 2023, approximately 19.2 million Americans had CUD (SAMHSA.gov). People with CUD commonly experience significant withdrawal symptoms, known as CWS, that can make it extremely difficult to reduce or discontinue cannabis. These withdrawal symptoms can be serious and potentially life-threatening, and can include an increase in suicidality, schizophrenia, psychosis, use disorder, violence, and other negative health consequences of chronic cannabis use, such as cannabis hyperemesis syndrome. Cannabis withdrawal symptoms have also been associated with a rapid relapse of cannabis use. PleoPharma believes that people should not have to suffer or experience serious events if for whatever reason they choose to reduce or stop cannabis.
